Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course

Journal of Psychiatric Research

Volumn 43, Issue 6, 2009, Pages 620-626

  Gebhardt, Stefan ^a   Haberhausen, Michael ^a   Heinzel Gutenbrunner, Monika ^a   Gebhardt, Nadine ^a,b   Remschmidt, Helmut ^a   Krieg, Jürgen Christian ^a   Hebebrand, Johannes ^c   Theisen, Frank M ^a,d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Herz Jesu Krankenhaus Fulda   (Germany)

Author keywords

Antipsychotics; Body mass index; Body weight gain; Long term; Parents; Predictors; Premorbid

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; APPETITE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SMOKING HABIT; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN;

EID: 60949099657     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.11.001     Document Type: Article

References (42)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156 (1999) 1686-1696
2. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and mangagement. Acta psychiatrica Scandinavica 100 (1999) 3-16
3. Basile V.S., Masellis M., McIntyre R.S., Meltzer H.Y., Lieberman J.A., and Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62 (2001) 45-66 [Suppl 23]
4. Basile V.S., Masellis M., De Luca V., Meltzer H.Y., and Kennedy J.L. -759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain. Lancet 360 (2002) 1790-1791
5. Blin O., and Micalle J. Antipsychotic-associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry 62 (2001) 11-21 Suppl 7
6. Bouchard C., Tremblay A., Després J.P., Nadeau A., Lupien P.J., Thériault G., et al. The response to long-term overfeeding in identical twins. New England Journal of Medicine 24 322 (1990) 1477-1482
7. Cabanac M., Duclaux R., and Spector N.H. Sensory feedback in regulation of body weight: is there a ponderostat?. Nature 229 (1971) 125-127
8. Chagnon Y.C. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Current Drug Targets 7 (2006) 1681-1695
9. Chagnon Y.C., Bureau A., Gendron D., Bouchard R.H., Mérette C., Roy M.A., et al. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 144B (2007) 1063-1069
10. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., and Miller del D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacology Bulletin 40 (2007) 57-62
11. Esen-Danaci{dotless} A., Sarandöl A., Taneli F., Yurtsever F., and Ozlen N. Effects of second generation antipsychotics on leptin and ghrelin. Progress in Neuro-psychopharmacology and Biological Psychiatry 32 (2008) 1434-1438
12. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission 114 (2007) 273-280
13. Frankenburg F.R., Zanarini M.C., Kando J., and Centorrino F. Clozapine and body mass change. Biological Psychiatry 43 (1998) 520-524
14. Gebhardt S., Haberhausen M., Krieg J.C., Remschmidt H., Heinzel-Gutenbrunner M., Hebebrand J., et al. Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. Journal of Neural Transmission 114 (2007) 1091-1095
15. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, et al. Body weight gain induced by atypical antipsychotics: an extension of the monocygotic twin and sib pair study. Journal of Clinical Pharmacy and Therapeutics, in press.
16. Homel P., Casey D., and Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophrenia Research 55 (2002) 277-284
17. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Journal of Psychopharmacology 20 (2006) 75-79
18. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., and Fleischhacker W.W. Weight gain induced by clozapine. European Neuropsychopharmacology 5 (1995) 437-440
19. Kawachi I., Colditz G.A., Stampfer M.J., Willett W.C., Manson J.E., Rosner B., et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Annals of Internal Medicine 119 (1993) 992-1000
20. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Molecular Psychiatry 2008. [Epub ahead of print].
21. Lipkovich I., Citrome L., Perlis R., Deberdt W., Houston J.P., Ahl J., et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. Journal of Clinical Psychopharmacology 26 (2006) 316-320
22. Maes H.H., Neale M.C., and Eaves L.J. Genetic and environmental factors in relative body weight and human adiposity. Behavior Genetics 27 (1997) 325-351
23. Martin A., Scahill L., Anderson G.M., Aman M., Arnold L.E., McCracken J., et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. American Journal of Psychiatry 161 (2004) 1125-1127
24. Murashita M., Inoue T., Kusumi I., Nakagawa S., Itoh K., Tanaka T., et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and Clinical Neurosciences 61 (2007) 54-58
25. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30 (2005) 106-110
26. Palik E., Birkás K.D., Faludi G., Karádi I., and Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Research and Clinical Practice 68 (2005) S60-S64 [Suppl 1]
27. Perez-Iglesias R., Vazquez-Barquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Terán J.M., et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Journal of Clinical Psychopharmacology 28 3 (2008) 289-295
28. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., et al. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 85 (2007) 249-256
29. Russell J.M., and Mackell J.A. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15 (2001) 537-551
30. Saddichha S., Ameen S., and Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 28 (2008) 27-31
31. Safer D.J. A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology 24 (2004) 429-436
32. Sørensen T.I. The genetics of obesity. Metabolism 44 (1995) 4-6 (9 Suppl 3)
33. Strassnig M., Miewald J., Keshavan M., and Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophrenia Research 93 1-3 (2007) 90-98
34. Stunkard A.J., Sørensen T.I., Hanis C., Teasdale T.W., Chakraborty R., Schull W.J., et al. An adoption study of human obesity. New England Journal of Medicine 314 (1986) 193-198
35. Theisen F.M., Gebhardt S., Brömel T., Otto B., Heldwein W., Heinzel-Gutenbrunner M., et al. A prospective study of serum ghrelin levels in patients treated with clozapine. Journal of Neural Transmission 112 (2005) 1411-1416
36. Theisen F.M., Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P.M., Krieg J.C., et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatric Genetics 15 (2005) 285-289
37. Theisen F.M., Linden A., König I.R., Martin M., Remschmidt H., and Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. Journal of Neural Transmission 110 (2003) 111-121
38. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154 (1997) 457-465
39. Umbricht D.S., Pollack S., and Kane J.M. Clozapine and weight gain. Journal of Clinical Psychiatry 55 (1994) 157-160 Suppl B
40. Wetterling T., and Müssigbrodt H.E. Weight gain: side effect of atypical neuroleptics?. Journal of Clinical Psychopharmacology 19 (1999) 316-321
41. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 2000.
42. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., et al. Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical. 60 (1999) 358-363